Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061210 | 0.81 | SMN1; SMN2 (0.42) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7064438 | 0.77 | CYP1A2 (0.49) | TP53MAPTRAB9ACYP1A2CYP3A4 | |
| SCHEMBL7061205 | 0.75 | RAB9A (0.40) | NAMPTRAB9ASMN1; SMN2 | |
| SCHEMBL7058272 | 0.72 | CYP2C19 (0.35) | CHRM4NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7059913 | 0.72 | TAAR1 (0.37) | CD274 | |
| SCHEMBL5754895 | 0.70 | HRH3 (0.48) | NPC1MAPTRAB9ACYP1A2CYP2C19 | |
| SCHEMBL5373022 | 0.69 | ADH1B (0.42) | MAPTRAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL13090073 | 0.68 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL6376648 | 0.68 | CHRNB2 (0.51) | CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7059655 | 0.68 | TSHR (0.41) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1248621-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001047523-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | OPRK1, OPRD1, ACHE | HDAC3 1340/4885HDAC1 1448/4885HDAC2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.